Request for Quotes: QuantiFERON®-TB Gold Plus Tests for LTBI Screening in the Community in Vietnam


QuantiFERON®-TB Gold Plus tests for LTBI screening in the community in Vietnam

RFQ Release Date:                   October 7, 2020

Questions Due Date:             October 10, 2020. Submission of questions or requests for clarification must be submitted in writing via email to [email protected] with a copy to [email protected] by 5:00 pm Hanoi. Please note that inquiries and answers to inquiries will be shared with all applicants. Please do not contact any FHI 360 employees regarding this RFQ.  Contacting individual employees may be cause for disqualification. No Telephone Inquiries Will Be Answered. 

Proposal Due Date:                 October 14, 2020. Complete proposals must be submitted via email to [email protected] with a copy to [email protected] no later than 5:00 pm Hanoi.

Contract Start Date:                October 26, 2020


The Family Health International (FHI 360) office in Vietnam with funding from USAID under the contract #AID-440-C-16-00001 “Sustainable HIV and Tuberculosis Response from Technical
Assistance (SHIFT) Project”
requires QuantiFERON®-TB Gold Plus tests for TB screening in the community. 


Our goal is to support the Government of Vietnam to successfully detect, treat and prevent TB, working at all levels of the health system to build technical expertise?. This will be done by expanding upon the NTP’s “Double X (2X) Strategy”, in which chest X-ray (CXR) is the first screening test for TB, followed by GeneXpert. The 2X uses CXR first to identify those with abnormal lung findings, avoiding potentially unnecessary GeneXpert testing.

The LTBI treatment and diagnosis for household contacts will be implement combine with the case finding among household contacts. At the case finding community campaign, elderly (greater than 5 years old) household contacts will be screened for active TB by CXR first, regardless symptoms at the community campaign; If screened negative for symptoms and normal CRX, they will undergo QuantiFERON®-TB Gold Plus tests; if positive QFT, they will be referred for LTBI treatment.



FHI 360 is requesting quotations from qualified vendors.

Vendors must submit to FHI 360 the following:

  • A brief description of the organization, its capabilities, and its ability to QuantiFERON®-TB Gold Plus tests for TB screening (not to exceed 2 pages)
  • Quotation for the services required. The quotation should be include a full-service package covering blood collection and completion of the assay, including QuantiFERON®-TB Gold Plus test kits, consumable for blood collection and ELISA.

Submitted quotes should be valid for 30 days from the date of submission to allow adequate time for organizational approval.

* Quotes should include payment terms. Indicate bank charges/fees, if applicable, for receiving an electronic bank transfer.


Selection will be based on best value, weighing price against technical factors as outlined below:

  1. Organizational Capability (20 points)
  2. Budget (30 points)


A fixed-price purchase order may be awarded in USD to the responsive vendor whose quote will be evaluated as most advantageous to FHI 360 (lowest price, technically acceptable offer). In the event that service/deliverable requirements need to be shifted during the time period between the signature of a purchase order with the selected vendor and the actual event, FHI 360 will modify the purchase order.


Responses to this RFQ should be submitted by email to [email protected] with a copy to [email protected] no later than 5:00 pm Hanoi. with subject line “QuantiFERON®-TB Gold Plus tests for LTBI screening in the community in Vietnam.” Any quotations received after this date and time may not be accepted and shall be considered non-responsive. FHI 360 will acknowledge receipt of the quotation by return email within 24 hours.


  • FHI 360 may cancel an RFQ and/or not make awards.
  • FHI 360 may reject any or all of the responses to its RFQ.
  • Issuance of an RFQ does not constitute award commitment by FHI 360.
  • FHI 360 reserves the right to disqualify any application based on offeror failure to follow RFQ instructions.
  • FHI 360 will not reimburse applicants for the cost of preparing and submitting an application to an RFQ. 
  • FHI 360 reserves the right to issue an award on the basis of an initial evaluation of offers without further discussion.
  • FHI 360 may award grants for only part of the activities listed in an RFQ.
  • FHI 360 reserves the right to check an applicant’s donor references.
  • FHI 360 also reserves the right to reject any or all applications received without explanation.
  • FHI 360 has the right to issue amendments to the RFQ at any time.


FHI 360 may contact offerors to confirm validity of the offer, contact person, address, and bid amount.


Job Details
Organisation Name: 
FHI 360
Application Deadline: 
Wed, 2020-10-14